Joseph A. Tyndall - Dec 9, 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Director
Signature
/s/ Marc Began as attorney-in-fact for Joseph A. Tyndall
Stock symbol
AXGN
Transactions as of
Dec 9, 2025
Transactions value $
-$558,548
Form type
4
Date filed
12/10/2025, 05:20 PM
Previous filing
Jun 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TYNDALL JOSEPH A. Director C/O AXOGEN, INC. 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA /s/ Marc Began as attorney-in-fact for Joseph A. Tyndall 2025-12-10 0001955281

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $100K +14.2K $7.04 14.2K Dec 9, 2025 Direct
transaction AXGN Common Stock Options Exercise $119K +10.9K +76.22% $10.95 25.1K Dec 9, 2025 Direct
transaction AXGN Common Stock Sale -$441K -14.2K -56.75% $30.98 10.9K Dec 9, 2025 Direct F1
transaction AXGN Common Stock Sale -$336K -10.9K -100% $30.98 0 Dec 9, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -14.2K -100% $0.00 0 Dec 9, 2025 Common Stock 14.2K $7.04 Direct F2
transaction AXGN Stock Option (right to purchase) Options Exercise $0 -10.9K -25.16% $0.00 32.3K Dec 9, 2025 Common Stock 10.9K $10.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.485 to $31.305 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Non-qualified stock option portion of the 2024 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant vested on June 6, 2025, the one-year anniversary of the grant date.
F3 Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 13, 2023.